. Numerous studies have addressed the role of chaperome members in isolation, yet little is known about their relationships regarding how they interact and function together in malignancy [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] . As function is probably highly dependent on endogenous conditions found in native tumours, chaperomes have resisted investigation, mainly due to the limitations of methods needed to disrupt or engineer the cellular environment to facilitate analysis. Such limitations have led to a bottleneck in our understanding of chaperome-related disease biology and in the development of chaperome-targeted cancer treatment. Here we examined the chaperome complexes in a large set of tumour specimens. The methods used maintained the endogenous native state of tumours and we exploited this to investigate the molecular characteristics and composition of the chaperome in cancer, the molecular factors that drive chaperome networks to crosstalk in tumours, the distinguishing factors of the chaperome in tumours sensitive to pharmacologic inhibition, and the characteristics of tumours that may benefit from chaperome therapy. We find that under conditions of stress, such as malignant transformation fuelled by MYC, the chaperome becomes biochemically 'rewired' to form a network of stable, survivalfacilitating, high-molecular-weight complexes. The chaperones heat shock protein 90 (HSP90) and heat shock cognate protein 70 (HSC70) are nucleating sites for these physically and functionally integrated complexes. The results indicate that these tightly integrated chaperome units, here termed the epichaperome, can function as a network to enhance cellular survival, irrespective of tissue of origin or genetic background. The epichaperome, present in over half of all cancers tested, has implications for diagnostics and also provides potential vulnerability as a target for drug intervention.
Transient, multi-protein complexes are important facilitators of cellular functions. This includes the chaperome, an abundant protein family comprising chaperones, co-chaperones, adaptors, and folding enzymes-dynamic complexes of which regulate cellular homeostasis together with the protein degradation machinery [1] [2] [3] [4] [5] [6] . Numerous studies have addressed the role of chaperome members in isolation, yet little is known about their relationships regarding how they interact and function together in malignancy [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] . As function is probably highly dependent on endogenous conditions found in native tumours, chaperomes have resisted investigation, mainly due to the limitations of methods needed to disrupt or engineer the cellular environment to facilitate analysis. Such limitations have led to a bottleneck in our understanding of chaperome-related disease biology and in the development of chaperome-targeted cancer treatment. Here we examined the chaperome complexes in a large set of tumour specimens. The methods used maintained the endogenous native state of tumours and we exploited this to investigate the molecular characteristics and composition of the chaperome in cancer, the molecular factors that drive chaperome networks to crosstalk in tumours, the distinguishing factors of the chaperome in tumours sensitive to pharmacologic inhibition, and the characteristics of tumours that may benefit from chaperome therapy. We find that under conditions of stress, such as malignant transformation fuelled by MYC, the chaperome becomes biochemically 'rewired' to form a network of stable, survivalfacilitating, high-molecular-weight complexes. The chaperones heat shock protein 90 (HSP90) and heat shock cognate protein 70 (HSC70) are nucleating sites for these physically and functionally integrated complexes. The results indicate that these tightly integrated chaperome units, here termed the epichaperome, can function as a network to enhance cellular survival, irrespective of tissue of origin or genetic background. The epichaperome, present in over half of all cancers tested, has implications for diagnostics and also provides potential vulnerability as a target for drug intervention.
To investigate the chaperome in tumours we first analysed HSP90, the most abundant chaperome member in human cells 1, 2 . In cultured non-transformed cells and in normal primary breast tissue (NPT, the normal tissue surrounding or adjacent to the corresponding primary tumour) (Fig. 1a, b ), HSP90 focused primarily as a single species at the predicted isoelectric point (pI) of 4.9. However, cancer cell lines analysed by this method contained a complex mixture of HSP90 species spanning a pI range of 4.5 to 6; HSP90α and HSP90β isoforms were part of these complexes. Furthermore, although all cancer cell lines contained a number of HSP90 complexes with pI < 4.9, a subset was enriched in HSP90 complexes with the unusual pI of ≥5, herein referred to as 'type 1' cells. We refer to cancer cell lines that contained mainly complexes with pI < 4.9 as 'type 2' cells. This distinction in HSP90 complexes was also evident in primary tumours (Fig. 1b) . The total levels of HSP90 were essentially identical among all analysed samples, irrespective of whether they were type 1 or type 2 ( Fig. 1a ; see further analyses).
Under denaturing conditions, HSP90 in type 1 tumours focused mainly at the pI of ~ 4.9 (Fig. 1c) . We therefore directed our attention on proteins interacting with HSP90 as the main instrument for pI change in type 1 tumours. HSP90 is known to interact with several co-chaperones including activator of HSP90 ATPase homologue 1 (AHA1, also known as AHSA1), cell division cycle 37 (CDC37), and HSP70-HSP90 organizing protein (HOP, also known as stress-inducible phosphoprotein 1 (STIP1)) which links HSP90 to the HSP70 machinery. Each of these co-chaperones has a distinct role. CDC37 facilitates activation of kinases, AHA1 augments HSP90 ATPase activity, and HSP70 and HOP participate in the chaperoning of proteins [2] [3] [4] [5] 13 . We observed that cultured cells and primary tumours enriched in the high pI HSP90 species were also enriched in high-molecular-weight, multimeric forms of HSP90 and of other essential chaperome members ( Fig. 1d and Extended Data Fig. 2c-e) .
We found that PU-H71, an HSP90 inhibitor that binds to HSP90 more strongly when HSP90 is complexed with co-chaperones and onco-client proteins 7, 18, 19 , also bound HSP90 more tightly in type 1 than in type 2 cells (Extended Data Fig. 3a-j) . This was independent of chaperome expression or intracellular ATP levels (as PU-H71 is an ATP competitor) (Extended Data Fig. 4) . At the molecular level, and unlike the anti-HSP90 antibody H9010, the small fraction of cellular HSP90 that was part of the high-molecular-weight species enriched in type 1 tumours was most sensitive to PU-H71 (Extended Data Fig. 3c, h ).
Our data suggested that a biochemically altered chaperome exists in type 1 tumours, so we investigated its composition ( Fig. 1e-h ). HSP90 protein isolates in type 1 tumours contained a significant enrichment of a number of chaperome proteins known to function as chaperone, co-chaperone, scaffolding, adaptor, interface mediators, foldase and isomerase proteins. Surprisingly, they also incorporated a large number of HSP70 chaperone regulators, in addition to the expected and known HSP90 regulators (Supplementary Discussion). Similarly, an HSP70-directed bait isolated numerous HSP90 regulators in type 1 tumours ( Fig. 1f and Extended Data Fig. 5a-e) . Multiple connectivity networks that integrate the HSP90 and HSP70 machineries and expand their functional reach through participating scaffolding proteins were characteristic of type 1 but not of type 2 tumours or non-transformed cells (Fig. 1g) . High-molecular-weight complexes that incorporate HSP90, HOP, HSC70 (heat shock cognate 70 kDa protein, the constitutively expressed HSP70 paralogue also known as HSPA8) 2 and its co-chaperone HSP110 (heat shock 105 kDa/110 kDa protein 1)
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Together, these results lend support for the existence in type 1 tumours of HSP90-and HSP70-centric complexes that incorporate the co-chaperones of both machineries and integrate the chaperome into a large functional and physical network (Fig. 1h) . Through scaffolding, adaptor, and interface modulator proteins, they bridge the chaperome to numerous cellular processes vital for tumour cell function. We refer to this highly integrated chaperome network of type 1 tumours as the epichaperome. Only a fraction of the entire chaperome pool participates in the chaperome rewiring of type 1 tumours. In contrast to the integrated epichaperome found in type 1 cells, no such integration is found in normal cells and type 2 tumours. In those cases, the HSP90 machinery only loosely interacts with the HSP70 machinery, mainly through the ubiquitous HSP90-HOP-HSP70 connection. In type 2 tumours, the two major chaperome machineries co-exist as insular chaperome communities that are only partially connected to each other.
Next, we investigated the functional relevance of the integrated epichaperome as compared to that of individual chaperome members or individual chaperome machineries. First, we investigated the reliance of type 1 and type 2 tumours on individual chaperome members (Fig. 2 ). In cells with essentially identical HSP90 levels, targeting of both HSP90α and protein levels (see Extended Data Fig. 5g ). Error bars show mean ± s.d., unpaired t-test, n = 6. **P < 0.01; ***P < 0.001. LDH, lactate dehydrogenase. e, Epichaperome, total chaperome levels, chaperome activity and cell viability of type 1 cells in which several concentrations of siRNAs (n = 7) against HSP90α and HSP90β were titrated in. f, Correlative analysis between epichaperome levels and cell viability for data in e (Pearson's r, two-tailed, n = 14). See also Extended Data Fig. 7 . For uncropped gel data, see Supplementary Fig. 1 . g, Summary schematic. b c a e g P T 6 6 P T 1 4 P T 3 0 P T 5 9 P T 6 0 P T 6 1 
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and HSP90β was toxic to type 1 but not type 2 tumours (Fig. 2a) . We confirmed this in mice bearing xenograft tumours (Fig. 2b) , in primary specimens ex vivo (Fig. 2c) , and in human patients (Extended Data Fig. 6a ). By contrast, while being toxic only to type 1 tumours, targeting of HSP90 inactivated its chaperone activity in both tumour types (see inhibition and/or degradation of HSP90 regulated proteins and pathways, such as EGFR and PI3K/AKT, and cell growth inhibition with similar half-maximum inhibitory concentration (IC 50 ) potencies; Extended Data Fig. 6b-i) . As observed for HSP90, downregulation of other individual chaperome members led to cell death in type 1 but not in type 2 cells (Fig. 2d) . When we interfered with epichaperome formation by reducing the levels of one of its components, AHA1, cells became less amenable to killing by PU-H71 (Extended Data Fig. 7a ). From these observations, we propose that the epichaperome has a role as the survival facilitator of type 1 tumours. In type 1 tumours, we observed that a striking decline (> 95% at protein level, Fig. 2e and Extended Data Fig. 7b -f) in overall total HSP90 levels was initially paralleled by an increase in the epichaperome. This occurred by an increased production of chaperome members that presumably sequestered the remaining HSP90 into the high-molecular-weight complexes. Under these conditions of low total HSP90 but high epichaperome levels, no cell death was observed. HSP90 function was also not impaired (see EGFR and p-S6K). As HSP90 levels continued to drop, however, an inflection was observed. At this point, the epichaperome levels dropped, chaperome members were depleted, a sudden drop in HSP90 function occurred, and cell death ensued. Epichaperome expression significantly correlated with cell viability (Fig. 2f) . In contrast, in type 2 cells, a similar drastic reduction of HSP90 levels halted its activity, but failed to re-wire the chaperome into the epichaperome and did not result in cell death (Extended Data Fig. 7g ). Together, these findings are consistent with the formation of the epichaperome as a survival mechanism for type 1 tumours. When the epichaperome is dismantled by ablation of a chaperome component, the network collapses and leads to cell death. In type 2 tumours in which the integration of the chaperome is only partial and most chaperome members function as insular communities, depletion of a chaperome member only 'locally' compromises the chaperome, while overall cellular survival is maintained (Fig. 2g) .
To understand the molecular mechanisms leading to epichaperome formation, we investigated the HSP90 interactome in type 1 and type 2 cells (Extended Data Fig. 5b ). We identified MYC as a transcription factor that could most probably explain the protein signature observed in type 1 tumours. MYC target genes were significantly enriched in type 1 tumours, as was a MYC transcriptional signature and positive regulators of MYC expression/function (Extended Data Fig. 8 ). We experimentally confirmed a significantly higher MYC transcriptional activity in type 1 versus type 2 cancer cells (Fig. 3a) . Knockdown of MYC re-wired type 1 cells into type 2; this was reflected in the composition of the chaperome complexes, the binding to PU-H71 and reduced sensitivity to HSP90 inhibition ( Fig. 3b-d) . We also observed a decrease in MYC mRNA and protein levels in type 1 cells that became resistant to HSP90 inhibitors after long-term treatment with suboptimal HSP90 inhibitor concentrations, and demonstrated their rewiring into type 2 cells (Fig. 3b-d and Extended Data Fig. 9a-e) . However, the introduction of a functional MYC gene into a type 2 cancer cell rewired it to become type 1 (Fig. 3b-d and Extended Data Fig. 9f-l) . Oncogenes that require single chaperome machinery activity for sufficient transformative power (for example, vSRC and mutated MET kinase require HSP90 (ref.
3)) were unable to induce the formation of the epichaperome, nor was epichaperome formation necessary to buffer their oncogenic function (Extended Data Fig. 9m-p) . Together these findings suggest that the transcription factor, MYC, at least in part, causes the molecular rewiring of the chaperome into the epichaperome as observed in type 1 tumours (Fig. 3e) .
The data point to the epichaperome and not the individual chaperome members as potential targets of chaperome-directed intervention in cancer. We thus assessed the prevalence of tumours expressing the epichaperome complexes. In probing cancer cell lines representing pancreatic, gastric, lung, and breast cancers, as well as lymphomas and leukaemias, we found that approximately 60-70% presented medium to high levels of epichaperome complexes (Fig. 4a) . Similar results were obtained with primary liquid tumours (Fig. 4b ) and solid tumours including lymphomas (Fig. 4c ). This establishes that over half of tumours tested use the epichaperome irrespective of their subtype, provenance or genetic background. Toxicity to HSP90 inhibition correlated with the presence of the epichaperome (P = 0.0006; R 2 = 0.71) but was independent of the levels of chaperome members, HSP90 client proteins, anti-apoptotic proteins and genetic alterations. This correlation held in over 90 cell lines encompassing breast cancer, lung cancer, pancreatic and gastric cancers, leukaemia and lymphomas (P < 0.0001; R 2 = 0.44) and was true for several HSP90 inhibitors 19, 20 (Extended Data Fig. 10 ). The data thus indicate that it is the abundance of the epichaperome, and not merely its existence, that is indicative of the reliance of tumours on the epichaperome. If patients were to be selected for epichaperome therapy, not only the existence of this species but also its abundance should be measured. To further confirm these findings, we collected primary breast cancer specimens (n = 40) obtained from surgery. Of these, 23 specimens were suitable samples to be evaluated for PU-H71 sensitivity and/or epichaperome abundance by isoelectric focusing (IEF) (that is, HSP90 of a pI > 4.9) and total HSP90 by SDS-PAGE (Fig. 4d) . In these specimens, we found a spectrum of sensitivities, ranging from 0% to 100% for apoptotic response, with 56% undergoing at least 50% apoptosis when challenged with 0.5 μ M PU-H71. Abundance of the epichaperome but not of total HSP90 significantly correlated with sensitivity ( Fig. 4d, P < 0.0001) .
Here we report the discovery of a new mechanism of tumour regulation. Our study unveils a novel usage of the chaperome in epichaperome networks for cancer cell survival. The epichaperome results from changes in the chaperome that are driven by a change in the cellular milieu, that is, activation of MYC, rather than defects in the chaperome members, composition, number or structure. It manifests as an enhanced physical integration of the HSP90 and HSP70 machineries, resulting in the utilization of their capacities in the tumour cell environment, and thereby also presenting a vulnerability that might possibly be exploited therapeutically with pharmacological modulators. Our results offer a blueprint for the future development of therapeutic inhibitors specific for multimeric chaperome complexes, and might encourage further drug developments and advances in innovative companion diagnostics (Extended Data Fig. 1 ).
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. 

MethOdS
Reagents. HSP90 inhibitors used in this study including PU-H71, PU-DZ13, NVP-AUY922, and SNX-2112 were synthesized as previously reported 7, 19 . 17-DMAG was purchased from Sigma. HSP90 bait (PU-H71 beads) 21 , HSP70 bait (YK beads) 22 , biotinylated YK (YK-biotin) 22 , fluorescently labelled PU-H71 (PU-FITC) 23 , the control derivatives PU-TEG and PU-FITC9 (ref. 24) , and the radiolabelled PU-H71-derivative 124 I-PU-H71 (ref. 25) were generated as previously described. The specificity of PU-H71 for HSP90 and over other proteins was extensively analysed 7 . Thus binding of PU-H71 in cell homogenates, live cells and organisms denotes binding to HSP90 species characteristic of each analysed tumour or tissue. Combined with the findings that PU-H71 binds more tightly to HSP90 in type 1 than in type 2 cells, an observation true for cell homogenates, live cells, and in vivo, at the organismal level, we propose that labelled versions of PU-H71 are reliable tools to perturb, identify and measure the expression of the high-molecular-weight, multimeric HSP90 complexes in tumours. The specificity of YK probes for HSP70 was previously reported 22, [26] [27] [28] . Cell lines. Cell lines were obtained from laboratories at WCMC or MSKCC, or were purchased from the American Type Culture Collection (ATCC) or Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ). Cells were cultured as per the providers' recommended culture conditions. Cells were authenticated using short tandem repeat profiling and tested for mycoplasma. 29, 30 . Primary breast cancer specimens. Patient tissue was obtained with informed consent and authorized through institutional review board (IRB)-approved bio-specimen protocol number 09-121 at Memorial Sloan Kettering Cancer Centre (New York, New York). Specimens were treated for 24 h or 48 h with the indicated concentrations of PU-H71 as previously described 31 . Following treatment, slices were fixed in 4% formalin solution for 1 h, then stored in 70% ethanol. For tissue analysis, slices were embedded in paraffin, sectioned, slide-mounted, and stained with haematoxylin and eosin (H&E). Apoptosis and necrosis of the tumour cells (as percentage) was assessed by reviewing all the H&E slides of the case (controls and treated ones) in toto, blindly, allowing for better estimation of the overall treatment effect to the tumour. In addition, any effects to precursor lesions (if present) and any off-target effects to benign surrounding tissue, were analysed. Tissue slides were assessed blindly by a breast cancer pathologist who determined the apoptotic events in the tumour, as well as any effect on adjacent normal tissue 31 .
Primary acute myeloid leukaemia (AML).
Cryopreserved primary AML samples were obtained with informed consent and Weill Cornell Medical College IRB approval (IRB number 0910010677 and IRB number 0909010629). Samples were thawed and cultured for in vitro treatment as described previously 32 .
Clinical trials. The microdose 124
I-PU-H71 PET-CT (Dunphy, M. PET imaging of cancer patients using 124I-PUH71: a pilot study available from: http://clinicaltrials. gov; NCT01269593) and phase I PU-H71 therapeutic (Gerecitano, J. The first-inhuman phase I trial of PU-H71 in patients with advanced malignancies available from: http://clinicaltrials.gov; NCT01393509) studies were approved by the institutional review board (protocols 10-139 and 11-041, respectively), and conducted under an exploratory investigational new drug (IND) application approved by the US Food and Drug Administration. Patients provided signed informed consent before participation.
124
I-PU-H71 tracer was synthesized in-house by the institutional cyclotron core facility at high specific activity. Epichaperome detection by PU-PET ( 124 I-PU-H71 positron emission tomography). For PU-PET, research PET-CT was performed using an integrated PET-CT scanner (Discovery DSTE, General Electric). CT scans for attenuation correction and anatomic coregistration were performed before tracer injection. Patients received 185 megabecquerel (MBq) of 124 I-PU-H71 by peripheral vein over two minutes. PET data were reconstructed using a standard ordered subset expected maximization iterative algorithm. Emission data were corrected for scatter, attenuation, and decay.
124 I-PU-H71 scans (PU-PET) were performed at 24 h after tracer administration. Each picture shown in Fig. 4c and Extended Fig. 6a is a scan taken of an individual patient. PET window display intensity scales for FDG and PU-PET fusion PET-CT images are given for both PU-PET and FDG-PET. Numbers in the scale bar indicate upper and lower SUV thresholds that define pixel intensity on PET images. The phase I trial included patients with solid tumours and lymphomas who had undergone prior treatment and currently had no curative treatment options. Patient cohorts were treated with PU-H71 at escalating dose levels determined by a modified continuous reassessment model. Each patient was treated with his or her assigned dose of PU-H71 on day 1, 4, 8, and 11 of each 21-day cycle. Neurons. Human embryonic stem cells (hESCs) were differentiated with a modified dual-SMAD inhibition protocol towards floor plate-based midbrain dopaminergic (mDA) neurons as described previously 33 . hESCs were maintained on mouse embryonic fibroblasts and passaged with Dispase (STEMCELL Technologies). For each differentiation, hESCs were harvested with Accutase (Innovative Cell Technology). At day 30 of differentiation, hESC-derived mDA neurons were replated and maintained on dishes precoated with polyornithine (PO; 15 μ g ml ), laminin (1 μ g ml ), and fibronectin (2 μ g ml ; R&D), dibutyryl cAMP (0.5 mM; Sigma), and DAPT (10 nM; Tocris). Two days after replating, mDA neurons were treated with 1 μ g ml −1 mitomycin C (Tocris) for 1 h to kill any remaining non-post mitotic contaminants. Assays were performed at day 65 of neuron differentiation. Epichaperome abundance measurement using the PU-FITC flow cytometry assay. The PU-FITC assay was performed as previously described 7, 23 . Briefly, cells were incubated with 1 μ M PU-FITC at 37 °C for 4 h. Then cells were washed twice with FACS buffer (PBS/0.5% FBS), and resuspended in FACS buffer containing 1 μ g ml −1 DAPI. HL-60 cells were used as internal control to calculate fold binding for all cell lines tested. The mean fluorescence intensity (MFI) of PU-FITC in treated viable cells (DAPI negative) was evaluated by flow cytometry. For primary AML specimens, cells were also stained with anti-CD45-APC-H7, to identify blasts and lymphocyte populations (BD biosciences). Blasts and lymphocyte populations were gated based on SSC versus CD45. The fold PU-FITC binding of leukaemic blasts (CD45dim) was calculated relative to lymphocytes (CD45hiSSClow). The FITC derivative FITC9 was used as a negative control. PU-FITC microscopy. Cells were seeded on coverslips in 6-well plate and cultured overnight. Cells were treated with 1 μ M PU-FITC or negative control (PU-FITC9, an HSP90 inert PU-H71 derivative labelled with FITC). At 4 h post-treatment, cells were fixed with 4% formaldehyde at room temperature for 30 min, and the coverslips were mounted on slides with DAPI-Fluoromount-G Mounting Media (Southern Biotech). The images were captured using EVOS FL Auto imaging system (ThermoFisher Scientific) or a confocal microscope (Zeiss LSM5). HSP90 immunofluorescence staining. Cells were seeded on coverslips and cultured overnight. Cells were fixed with 4% formaldehyde at room temperature for 30 min, washed three times with PBS, and permeabilized with 0.2% Triton X-100 in blocking buffer (PBS/5% BSA) for 10 min. Cells were incubated in blocking buffer for 30 min, and then incubated with rabbit anti-human HSP90α antibody (1:500, Abcam 2928) and mouse anti-human HSP90β (1:500, Stressmarq H9010), or rabbit and mouse normal IgG, in blocking buffer for 1 h. Cells were washed three times with PBS, and incubated with goat anti-mouse Alexa Fluor 568 and goat antirabbit Alexa Fluor 488 (1:1,000, ThermoFisher Scientific) in blocking buffer in the dark for 1 h. Cells were then washed three times with PBS, and the coverslips were removed from the plate, and mounted on slides with DAPI-Fluoromount-G Mounting Media (Southern Biotech). The images were captured using EVOS FL Auto imaging system (ThermoFisher Scientific) or a confocal microscope (Zeiss LSM5). Fluorescence intensity was quantified by the integrated density algorithm as implemented in ImageJ. PU-FITC or GM-cy3B binding to HSP90 in cell homogenates. Assays were carried out in black 96-well microplates (Greiner Microlon Fluotrac 200). A stock of 10 μ M PU-FITC (or GM-cy3B 34 ) was prepared in DMSO and diluted with Felts buffer (20 mM Hepes (K), pH 7.3, 50 mM KCl, 2 mM DTT, 5 mM MgCl 2 , 20 mM Na 2 MoO 4 , and 0.01% NP40 with 0.1 mg ml −1 BGG). To each well was added the fluorescent dye-labelled HSP90 ligand (3 nM PU-FITC or 6 nM GM-cy3B), and cell lysates (7.5 μ g) in a final volume of 100 μ l Felts buffer. For each assay, background wells (buffer only), and tracer controls (PU-FITC only) were included on assay plate. To determine the equilibrium binding of GM-cy3b, increasing amounts of lysate (up to 20 μ g of total protein) were incubated with tracer. The assay plate was placed on a shaker at room temperature for 60 min and the FP values in mP were measured every 5 min. At time t = 60 min, dissociation of fluorescent ligand was initiated by adding 1 μ M PU-H71 in Felts buffer to each well and then placing the assay plate on a shaker at room temperature and measuring the FP values in mP every 5 min. The assay window was calculated as the difference between the FP value recorded for the bound fluorescent tracer and the FP value recorded for the free fluorescent tracer (defined as mP − mPf). Measurements were performed on a Molecular Devices SpectraMax Paradigm instrument (Molecular Devices, Sunnyvale, CA), and data were imported into SoftMaxPro6 and analysed in GraphPad Prism 5. Protein analysis by the NanoPro capillary-based immunoassay platform. To identify and separate chaperome complexes in tumours, and to overcome the limitations of classical protein chromatography methods for resolving complexes of similar composition and size, we took advantage of a capillary-based platform that combines isoelectric focusing (IEF) with immunoblotting capabilities 35 . This methodology uses an immobilized pH gradient to separate native multimeric protein complexes based on their isoelectric point (pI), and allows for subsequent probing of immobilized complexes with specific antibodies. The method uses only minute amounts of sample, thus enabling the interrogation of primary specimens. Cultured cells were lysed in 20 mM HEPES pH 7.5, 50 mM KCl, 5 mM MgCl 2 , 0.01% NP40, 20 mM Na 2 MoO 4 buffer, containing protease and phosphatase inhibitors. Primary specimens were lysed in either Bicine-Chaps or RIPA buffers (ProteinSimple). Total protein assay was performed on an automated system, NanoPro 1000 Simple Western (ProteinSimple), for charge-based separation. Briefly, total cell lysates were diluted to a final protein concentration of 250 ng μ l −1 using a master mix containing 1× Premix G2 pH 3-10 separation gradient (Protein simple) and 1× isoelectric point standard ladders (ProteinSimple). Samples diluted in this manner maintained their native charge state, and were loaded into capillaries (ProteinSimple) and separated based on their isoelectric points at a constant power of 21,000 μ Watts for 40 min. Immobilization was performed by UV-light embedded in the Simple Western system, followed by incubations with anti-HSP90β (SMC-107A, StressMarq Biosciences), anti-HSP90α (ab2928, Abcam), anti-HSP70 (SPA-810, Enzo), AKT (4691) The blots were washed with TBS/0.1% Tween 20 and incubated with appropriate HRP-conjugated secondary antibodies. Chemiluminescent signal was detected with Enhanced Chemiluminescence Detection System (GE Healthcare) following the manufacturer's instructions. Native-cognate antibodies. We screened a panel of anti-chaperome antibodies for those that interacted with the target protein in its native form. We reasoned that these antibodies were more likely to capture stable multimeric forms of the chaperome members. These native-cognate antibodies were used in native-PAGE and IEF analyses of chaperome complexes. HSP90β (SMC-107) and HSP110 (SPC-195) antibodies were purchased from Stressmarq; HSP70 (SPA-810), HSC70 (SPA-815), HOP (SRA-1500), and HSP40 (SPA-400) from Enzo; HSP90β (ab2927), HSP90α (ab2928), and AHA1 (ab56721) from Abcam; CDC37 (4793) from Cell Signaling Technology. Native gel electrophoresis. Cells were lysed in 20 mM Tris pH 7.4, 20 mM KCl, 5 mM MgCl 2 , 0.01% NP40, and 10% glycerol buffer by a freeze-thaw procedure. Primary samples were lysed in either Bicine-Chaps or RIPA buffers (ProteinSimple). Twenty-five to one hundred μ g of protein was loaded onto 4-10% native gradient gel and resolved at 4 °C. The gels were immunoblotted as described above following either incubation in Tris-Glycine-SDS running buffer for 15 min before transfer in regular transfer buffer for 1 h, or directly transferred in 0.1% SDS-containing transfer buffer for 1 h. siRNA knockdown. Cells were plated at 1 × 10 6 per 6 well-plate and transfected with an siRNA against human AHA1 (AHSA1; 5′ -TTCAAATTGGTCCACGGATAA-3′ ), HSP90α (HSP90AA1; no. 1 5′ -ATGGCATGACAACTACTTTAA-3′ ; no. 2 5′ -AACC CTGACCATTCCATTATT-3′ ; no.3 5′ -TGCACTGTAAGACGTATGTAA-3′ ), HSP90β (HSP90AB1; no., 5′ -CAAGAATGATAAGGCAGTTAA-3′ ; no. 5′ -TACGTT GCTCACTATTACGTA-3′ ; no.3 5′-CAGAAGACAAGGAGAATTACA-3′ ) HSP90α /β (no.1 5′ -CAGAATGAAGGAGAACCAGAA-3′ , no.2 5′ -CACAACGA TGATGAACAGTAT-3′ ), HSP110 (HSPH1; 5′ -AGGCCGCTTTGTAGTTC AGAA-3′ ) from Qiagen or HOP (STIP1) (Dharmacon; M-019802-01), or a negative control (scramble; 5′ -CAGGGTATCGACGATTACAAA-3′ ) with Lipofectamine RNAiMAX reagent (Invitrogen), incubated for 72 h and subjected to further analysis. qRT-PCR. Total mRNA was isolated using TRIzol Reagent (Invitrogen) following the manufacturer's recommended protocol. Reverse transcription of mRNA into cDNA was performed using QuantiTect Reverse Transcription Kit (Qiagen). qRT-PCR was performed using PerfeCTa SYBR (Quanta Bioscience), 10 nM AHSA1 (forward: 5′ -GCGGCCGCTTCTAGTAGTTT-3′ and reverse: 5′ -CATCTCTCTCCGTCCAGTGC-3′ ) and GAPDH (forward: 5′ -CAAAGGCACAGTCAAGGCTGA-3′ and reverse: 5′ -TGGTGAAGACG CCAGTAGATT-3′ ) primers, or 1× QuantiTect Primers for HSP110 (HSPH1), HSP90α (HSP90AA1), HSP90β (HSP90AB1), HSP70 (HSPA1A), HOP (STIP1) (Qiagen) following recommended PCR cycling conditions. Melting curve analysis was performed to ensure product uniformity. Protein depletion. To investigate which of the two HSP70 paralogues is involved in epichaperome formation we performed immunodepletions with HSP70 and HSC70 antibodies. Protein lysates were immunoprecipitated consecutively three times with either an HSP70 (Enzo, SPA-810), HSC70 (Enzo, SPA-815) or HOP (kindly provided by M. B. Cox, University of Texas at El Paso), or with the same species normal antibody as a negative control (Santa Cruz). The resulting supernatant was collected and run on a native or a denaturing gel. Native gel electrophoresis and isoelectric focusing (IEF) under denaturing conditions. Tumour lysates were mixed with 10 M urea (dissolved in Felts buffer) to reach the indicated final concentrations of 2 M, 4 M and 6 M. After incubation for 10 min at room temperature or frozen overnight at − 80 °C, the lysates were loaded onto 4-10% native gradient gel and resolved at 4 °C or applied to the IEF capillary. The HSP90β bands were detected by using antibody purchased from Stressmarq (SMC-107). MYC knockdown by lentiviral-delivered shRNA. A lentiviral vector expressing the MYC shRNA, as previously described 36 , was requested from Addgene (Plasmid 29435, c-MYC shRNA sequence: GACGAGAACAGTTGAAACA). Viruses were prepared by co-transfecting the shRNA vector, the packaging plasmid psPAX2 and the envelop plasmid pMD2.G into HEK293 cells. OCI-LY1 cells were then infected with lentiviral supernatants in the presence of 4 μ g ml −1 polybrene for 24 h. Following flow cytometry selection for positive cells, cells were expanded for further experiments. The MYC protein level was confirmed at 10 days post-infection by western blot using the anti-MYC antibody (Cell Signaling Technology, 5605). Exogenous MYC expression. Viruses were prepared by co-transfection of the lentiviral vector expressing the MYC shRNA with pLM-mCerulean-2A-cMyc (Addgene, 23244) or pCDH-puro-cMYC (Addgene, 46970), the packaging plasmid psPAX2, and the envelope plasmid pMD2.G into HEK293 cells. ASPC1 cells were Letter reSeArCH then infected with lentiviral supernatants in the presence of 4 μ g ml −1 polybrene for 24 h and sorted for mCerulean positive cells or selected with puromycin treatment. Changes in cell size after infection were monitored by analysing the forward scatter (FSC) of intact cells via flow cytometry. MYC protein levels were analysed at 4 days post-infection by western blot. MYC transcription factor binding activity assay. Whole cell extracts were prepared by homogenizing cells in RIPA buffer (20 mM HEPES pH 7.5, 150 mM NaCl, 1% NP40, 0.25% sodium deoxycholate, 10% glycerol, protease inhibitors). MYC activity was determined using the TransAM c-Myc Kit (Active Motif, 43396), following the manufacturer's instructions. Cell viability assessment ATP assay. Cell viability was assessed using CellTiter-Glo luminescent Cell Viability Assay (Promega) after a 72 h PU-H71 treatment. The method determines the number of viable cells in culture based on quantification of the ATP present, which signals the presence of metabolically active cells, and was performed as previously reported 37 . For the annexin V staining, cells were labelled with Annexin V-PE and 7AAD after PU-H71 treatment for 48 h, as previously reported 38 . The necrotic cells were defined as annexin V 39 . No statistical methods were used to predetermine sample size. Animals were randomly assigned to groups. Studies were not conducted blinded. Small-animal PET imaging. Imaging was performed with a dedicated smallanimal PET scanner (Focus 120 microPET; Concorde Microsystems, Knoxville, TN). Mice were maintained under 2% isoflurane (Baxter Healthcare, Deerfield, IL) anaesthesia in oxygen at 2 litres per min during the entire scanning period. To reduce the thyroid uptake of free iodide arising from metabolism of tracer, mice received 0.01% potassium iodide solution in their drinking water starting 48 h before tracer administration. For PET imaging, each mouse was administered 9.25 MBq (250 μ Ci) of 124 I-PU-H71 via the tail vein. List-mode data (10 to 30 min acquisitions) were obtained for each animal at various time points post-tracer administration. An energy window of 420-580 keV and a coincidence timing window of 6 ns were used. The resulting list-mode data were sorted into 2-dimensional histograms by Fourier rebinning; transverse images were reconstructed by filtered back projection (FBP). The image data were corrected for non-uniformity of scanner response, dead-time count losses, and physical decay to the time of injection. There was no correction applied for attenuation, scatter, or partialvolume averaging. The measured reconstructed spatial resolution of the Focus 120 is 1.6-mm FWHM at the centre of the field of view. Region of interest (ROI) analysis of the reconstructed images was performed using ASIPro software (Concorde Microsystems, Knoxville, TN), and the maximum pixel value was recorded for each tissue/organ ROI. A system calibration factor (that is, μ Ci per ml per cps per voxel) that was derived from reconstructed images of a mouse-size water-filled cylinder containing 18 F was used to convert the 124 I voxel count rates to activity concentrations (after adjustment for the 124 I positron branching ratio). The resulting image data were then normalized to the administered activity to parameterize the micro-PET images in terms of per cent injected dose per gram (%ID per g) (corrected for decay of 124 I to the time of injection). Post-reconstruction smoothing was applied only for visual representation of images in the figures. Upon euthanasia, radioactivity ( 124 I) was measured in a gamma-counter (Perkin Elmer 1480 Wizard 3 Auto Gamma counter) using a 400-600 keV energy window. Count data were background-and decay-corrected to the time of injection, and the percent injected dose per gram (%ID per g) for each tumour sample was calculated using a calibration curve to convert counts to radioactivity, followed by normalization to the total activity injected. Efficacy studies. Mice (n = 5) bearing MDA-MB-468 or ASPC1 tumours reaching a volume of 100-150 mm 3 were treated i.p. using PU-H71 (75mg per kg) or vehicle, on a 3 times per week schedule, as indicated. Tumour volume (in mm 3 ) was determined by measurement with Vernier calipers, and was calculated as the product of its length × width 2 × 0.5. Tumour volume was expressed on indicated days as the median tumour volume ± s.d. indicated for groups of mice. Mice were euthanized after similar PU-H71 treatment periods, and at a time before tumours reached a size that resulted in discomfort or difficulty in physiological functions of mice in the individual treatment group, in accordance with our IUCAC protocol. LC-MS/MS analyses. Frozen tissue was dried and weighed before homogenization in acetonitrile/H 2 O (3:7). PU-H71 was extracted in methylene chloride, and the organic layer was separated and dried under vacuum. Samples were reconstituted in mobile phase. The concentrations of PU-H71 in tissue or plasma were determined by high-performance LC-MS/MS. PU-H71-d 6 was added as the internal standard 40 . Compound analysis was performed on the 6410 LC-MS/MS system (Agilent Technologies) in multiple reaction monitoring mode using positive-ion electrospray ionization. For tissue samples, a Zorbax Eclipse XDB-C18 column (2.1 × 50 mm, 3.5 μ m) was used for the LC separation, and the analyte was eluted under an isocratic condition (80% H 2 O + 0.1% HCOOH: 20% CH 3 CN) for 3 min at a flow rate of 0.4 ml min . Chemical bait precipitation and proteomics. Protein extracts were prepared either in 20 mM HEPES pH 7.5, 50 mM KCl, 5 mM MgCl 2 , 1% NP40, and 20 mM Na 2 MoO 4 for PU-H71 beads pull-down, or in 20 mM Tris pH 7.4, 150 mM NaCl, and 1% NP40 for YK beads pull-down. Samples were incubated with the PU-H71 beads (HSP90 bait) for 3-4 h or with the YK beads (HSP70 bait, for chemical precipitation) overnight, at 4 °C, then washed and subjected to SDS-PAGE with subsequent immunoblotting and western blot analysis. For HSP70 proteomic analyses, cells were incubated with a biotinylated YK-derivative, YK-biotin. Briefly, MDA-MB-468 cells were treated for 4 h with 100 μ M biotin-YK5 or d-biotin as a negative control. Cells were collected and lysed in 20 mM Tris pH 7.4, 150 mM NaCl, and 1% NP40 buffer. Protein extracts were incubated with streptavidin agarose beads (Thermo Scientific) for 1 h at 4 °C, washed with 20 mM Tris pH 7.4, 150 mM NaCl, and 0.1% NP40 buffer and applied onto SDS-PAGE. The gels were stained with SimplyBlue Coomassie stain (Invitrogen Life Science Technologies). Proteomic analyses were performed using the published protocol 7, 18, 22 . Control beads contained an inert molecule as previously described 7, 18, 22 . Protein identification by nano-liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) analysis. Affinity-purified protein complexes from type 1 tumours (n = 6; NCI-H1975, MDA-MB-468, OCI-LY1, Daudi, IBL1, BC3), type 2 tumours (n = 3; ASPC1, OCI-LY4, Ramos) and from non-transformed cells (n = 3; MRC5, HMEC and neurons) were resolved using SDS-polyacrylamide gel electrophoresis, followed by staining with colloidal, SimplyBlue Coomassie stain (Invitrogen Life Science Technologies) and excision of the separated protein bands. Control beads that contained an inert molecule were subjected to the same steps as PU-H71 and YK beads and served as a control experiment. To ensure that we captured a majority of the HSP90 complexes in each cell type, we performed these studies under conditions of HSP90-bait saturation. The number of gel sections per lane averaged to be 14. In situ trypsin digestion of gel bound proteins, purification of the generated peptides and LC-MS/MS analysis were performed using our published protocols 7, 18, 22 . After the acquisition of raw files, Proteowizard (version 3.0.3650) 41 was used to create a Mascot Generic Format (mgf) file containing accurate mass for each peak and its corresponding ms2 ions. Each mgf was then subjected to search a human segment of Uniprot protein database (20, 273 sequences, European Bioinformatics Institute, Swiss Institute of Bioinformatics and Protein Information Resource) using Mascot (Matrix Science; version 2.5.0; http://www.matrixscience.com). Decoy proteins were added to the search to allow for the calculation of false discovery rates (FDR). The search parameters were as follows: (i) two missed cleavage tryptic sites were allowed; (ii) precursor ion mass tolerance = 10 p.p.m.; (iii) fragment ion mass tolerance = 0.8 Da; and (iv) variable protein modifications were allowed for methionine oxidation, deamidation of asparagine and glutamines, cysteine acrylamide derivatization and protein N-terminal acetylation. MudPit scoring was typically applied using significance threshold score P < 0.01. Decoy database search was always activated and, in general, for merged LS-MS/MS analysis of a gel lane with P < 0.01, false discovery rate averaged around 1%. The Mascot search result was finally imported into Scaffold (Proteome Software, Inc.; version 4_4_1) to further analyse tandem mass spectrometry (MS/MS) based protein and peptide identifications. X! Tandem (The GPM, http://thegpm.org; version CYCLONE (2010.12.01.1) was then performed and its results are merged with those from Mascot. The two search engine results were combined and displayed at 1% FDR. Protein and peptide probability was set at 95% with a minimum peptide requirement of 1. Protein identifications were expressed as Exclusive Spectrum Counts that identified each 42 , were used for protein analyses. CHIP and PP5 were examined and used as internal quality controls among the samples. Statistics were performed using R (version 3.1.3) limma package 43, 44 . For entries with zero spectral counts, and to enable further analyses, we assigned an arbitrary small number of 0.1. The data were then transformed into logarithmic base 10 for analysis. Linear models were fit to the transformed data and moderated standard errors were calculated using empirical Bayesian methods. For Fig. 1f and Extended Data Fig. 5a , a moderated t-statistic was used to compare protein enrichment between type 1 cells and combined type 2 and non-transformed cells 45 . For Extended Data Fig. 5b , the t-statistic was performed to compare protein enrichment among type 1 cells, type 2 cells and non-transformed cells (see Supplementary Table 1 ). Heat maps were created to display the selected proteins using the package "gplots" and "lattice" 46, 47 . See Supplementary Table 1 48 . Proteins displayed in the heat map were uploaded in STRING database to generate the PPI networks. STRING builds functional protein-association networks based on compiled available experimental evidence. The thickness of the edges represents the confidence score of a functional association. The score was calculated based on four criteria: co-expression, experimental and biochemical validation, association in curated databases, and co-mentioning in PubMed abstracts 48 . Proteins with no adjacent interactions were not shown. The colour scale in nodes indicates the average enrichment of the protein (measured as exclusive spectral counts) in type 1, type 2, and non-transformed cells, respectively. The network layout for type 1 tumours was generated using edgeweighted spring-electric layout in Cytoscape with slight adjustments of marginal nodes for better visualization 49 . The layout for type 2 and non-transformed cells retains that of type 1 for better comparison. Proteins with average relative abundance values less than 1 were deleted from analyses. The biological processes in which they participate and the functionality of proteins enriched in type 1 tumours were assigned based on gene ontology terms and based on their designated interactome from UniProtKB, STRING, and/or I2D databases 48, [50] [51] [52] [53] . The Upstream Regulator analytic, as implemented in Ingenuity Pathways Analysis (IPA, QIAGEN Redwood City, http://www.qiagen.com/ingenuity), was used to identify the cascade of upstream transcriptional regulators that can explain the observed protein expression changes in type 1 tumours. The analysis is based on prior knowledge of expected effects between transcriptional regulators and their target genes stored in the Ingenuity Knowledge Base. The analysis examines how many known targets of each transcription regulator are present in the data set, and calculates an overlap P value for upstream regulators based on significant overlap between dataset genes and known targets regulated by a transcription regulator. For Extended Data HSP90AA1, HSP90AB1, HSPH1 , HSPA8, STIP1, AHSA1) were also evaluated. Statistical analysis. Data were visualized and statistical analyses performed using GraphPad Prism (version 6; GraphPad Software) or R statistical package. In each group of data, estimate variation was taken into account and is indicated in each figure as s.d. or s.e.m. If a single panel is presented, data are representative of 2 or 3 biological or technical replicates, as indicated. P values for unpaired comparisons between two groups with comparable variance were calculated by two-tailed Student's t-test. Pearson's tests were used to identify correlations among variables. Significance for all statistical tests was shown in figures for not significant (NS), * P < 0.05, * * P < 0.01, * * * P < 0.001 and * * * * P < 0.0001. No samples or animals were excluded from analysis, and sample size estimates were not used. Animals were randomly assigned to groups. Studies were not conducted blinded, with the exception of all patient specimen histological analyses.
